Amgen has made a play in a hot area of immunology R&D, paying $400 million upfront to claim rights to an OX40-targeting drug from Kyowa Kirin that is ready for phase 3 testing for atopic ...

Atopic dermatitis (AD) is a chronic, inflammatory skin condition driven by complex immune mechanisms involving T cells. In the context of AD, OX40, a costimulatory receptor present on activated T ...

STAR-0310, a high affinity monoclonal antibody OX40 antagonist that incorporates YTE technology, is in development for the potential treatment of atopic dermatitis (AD) and potentially other ...